Sources linked to the development of the anti-Covid vaccine at the University of Oxford have informed ANSA that the immunization data is “robust” and that the additional studies announced by AstraZeneca “will not impact the deadlines”. According to these sources, the results of the third stage clinical vaccine trials are due to be published in a scientific journal next week and submitted “soon” to the European Medicines Agency (EMA). The production of the immunizer is already underway, and the first doses will be made available as soon as there is approval from the health authorities. Last Monday (23), AstraZeneca, a multinational company responsible for the global production and distribution of the Oxford vaccine, disclosed that the drug had shown up to 90% effectiveness in preventing Covid-19. According to the company, peak efficiency was achieved with a half-dose regimen followed by a full dose with an interval of 15 days. However, it was discovered that this combination is the result of an error and that the elderly were not subjected to this dosage. This raised questions from the scientific community about the preliminary results of the clinical trial and made AstraZeneca announce the need for “complementary” studies for confirm the effectiveness.The Oxford vaccine is one of the most promising to contain the pandemic, especially for its low production cost and the fact that it can be kept under normal conditions of refrigeration (2 to 8ºC). The immunizer was initially developed in partnership with the Italian company Advent-IRBM, which produced the doses of the first phases of tests. In late April, the British university signed an agreement with AstraZeneca for the production and distribution of the candidate globally.